Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00485563 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by Endocyte.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00485563: Clinical Trial Phase 2 study, sponsored by Endocyte.
NCT00485563 is a Phase 2 study that was terminated before completion, run by Endocyte. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00485563, a Phase 2 study, was terminated before completion, sponsored by Endocyte.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a Phase 2 clinical trial to collect data on tumor responses produced by folate-hapten conjugate therapy (vaccination with EC90 \[KLH-FITC\] and GPI-0100 adjuvant followed by treatment with EC17 (folate-FITC) in combination with low-dose cytokines in patients with progressive metastatic renal cell carcinoma. All patients will undergo imaging with the investigational imaging agent 99mTc-EC20 (FolateScan) during the screening period to confirm eligibility for the treatment portion of the clinical trial.
Interventions
- DRUG Interleukin-2
- DRUG Interferon-alpha
- BIOLOGICAL EC90 (KLH-FITC)
- BIOLOGICAL GPI-0100
- DRUG EC17 (Folate-FITC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Why NCT00485563 stopped before completion
NCT00485563 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 5 interventions - of which Interleukin-2 is the first listed.
NCT00485563 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00485563 about?
NCT00485563 is a clinical study titled "A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma". This is a Phase 2 clinical trial to collect data on tumor responses produced by folate-hapten conjugate therapy (vaccination with EC90 \[KLH-FITC\] and GPI-0100 adjuvant followed by treatment with EC17 (folate-FITC) in combination with low-dose cytokines in patients with progressive metastatic renal...
What is the current status of trial NCT00485563?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2007-06. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00485563?
The interventions under investigation include: Interleukin-2 (DRUG), Interferon-alpha (DRUG), EC90 (KLH-FITC) (BIOLOGICAL), GPI-0100 (BIOLOGICAL), EC17 (Folate-FITC) (DRUG).
Who is sponsoring clinical trial NCT00485563?
This trial is sponsored by Endocyte, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00485563's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia